Literature DB >> 12384403

Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway.

Eric Sulpice1, Marijke Bryckaert, Julie Lacour, Jean-Olivier Contreres, Gerard Tobelem.   

Abstract

Platelet factor 4 (PF-4) is a member of the chemokine family with powerful antiangiogenic properties. The mechanism by which PF-4 inhibits endothelial cell proliferation is unclear. We investigated the effects of PF-4 on the intracellular signal transduction induced by basic fibroblast growth factor (FGF2). We found that PF-4 (10 microg/mL) inhibited the FGF2-induced proliferation of adrenal cortex capillary endothelial (ACE) cells. The inhibition of MEK1/2 (mitogen-activated protein kinase kinase) by PD98059 or of PI3K (phosphatidylinositol 3-kinase) by Ly294002 abolished the proliferation induced by FGF2, suggesting that ACE cell proliferation required dual signaling through both the extracellular signal-regulated kinase (ERK) and PI3K pathways. Ly294002 had no significant effect on ERK phosphorylation, whereas PD98059 had a weak effect on the phosphorylation of Akt, suggesting that 2 separate cascades are required for ACE cell proliferation. The addition of PF-4 (10 microg/mL) significantly inhibited ERK phosphorylation (95%), showing that PF-4 acted directly on or upstream from this kinase. Surprisingly, PF-4 did not affect FGF2-induced Akt phosphorylation. This suggests that PF-4 disrupts FGF2 signaling via an intracellular mechanism of inhibition. To exclude the possibility that PF-4 inhibited the binding of FGF2 to only one FGF receptor, preferentially activating the ERK pathway, we investigated the effect of PF-4 on FGF2-induced ERK and Akt phosphorylation, using mutant heparan sulfate-deficient Chinese hamster ovary cells transfected with the FGF-R1 cDNA. The addition of PF-4 (1 microg/mL) significantly inhibited ERK phosphorylation (90%), with no effect on Akt phosphorylation, suggesting that PF-4 acts downstream from the FGF-R1 receptor. In conclusion, this is the first report showing that PF-4 inhibits FGF2 activity downstream from its receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384403     DOI: 10.1182/blood.V100.9.3087

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Chemokines as mediators of angiogenesis.

Authors:  Borna Mehrad; Michael P Keane; Robert M Strieter
Journal:  Thromb Haemost       Date:  2007-05       Impact factor: 5.249

Review 2.  Chemokines as mediators of neovascularization.

Authors:  Ellen C Keeley; Borna Mehrad; Robert M Strieter
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-08-28       Impact factor: 8.311

3.  Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo.

Authors:  Longjiang Yang; Juan Du; Jian Hou; Hua Jiang; Jianfeng Zou
Journal:  BMC Cancer       Date:  2011-06-21       Impact factor: 4.430

Review 4.  Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.

Authors:  Marco Rusnati; Chiara Urbinati; Silvia Bonifacio; Marco Presta; Giulia Taraboletti
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-23

5.  Angiodrastic Chemokines in Colorectal Cancer: Clinicopathological Correlations.

Authors:  George Emmanouil; George Ayiomamitis; Adamantia Zizi-Sermpetzoglou; Maria Tzardi; Andrew Moursellas; Argyro Voumvouraki; Elias Kouroumalis
Journal:  Anal Cell Pathol (Amst)       Date:  2018-04-16       Impact factor: 2.916

Review 6.  FGF2, an Immunomodulatory Factor in Asthma and Chronic Obstructive Pulmonary Disease (COPD).

Authors:  Yuanyang Tan; Yongkang Qiao; Zhuanggui Chen; Jing Liu; Yanrong Guo; Thai Tran; Kai Sen Tan; De-Yun Wang; Yan Yan
Journal:  Front Cell Dev Biol       Date:  2020-04-02

7.  F-Prostaglandin receptor regulates endothelial cell function via fibroblast growth factor-2.

Authors:  Margaret C Keightley; Pamela Brown; Henry N Jabbour; Kurt J Sales
Journal:  BMC Cell Biol       Date:  2010-01-21       Impact factor: 4.241

8.  An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.

Authors:  Laura Lasagni; Michela Francalanci; Francesco Annunziato; Elena Lazzeri; Stefano Giannini; Lorenzo Cosmi; Costanza Sagrinati; Benedetta Mazzinghi; Claudio Orlando; Enrico Maggi; Fabio Marra; Sergio Romagnani; Mario Serio; Paola Romagnani
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

9.  Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases.

Authors:  Douglas G Walker; Lih-Fen Lue; Geidy Serrano; Charles H Adler; John N Caviness; Lucia I Sue; Thomas G Beach
Journal:  Front Neurosci       Date:  2016-01-14       Impact factor: 4.677

Review 10.  Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Betty Tai; Sathyen A Prabhu; Catherine M Capac; Matthew Gliksman; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.